-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The treatment of intracranial unbromed small aneurysms (small unruptured intracranial aneurysms, UIAs) has been a controversial topic in the field of neurosurgery.
standard treatment is to observe these lesions.
less than 7mm accounted for 69.6% of ruptured aneurysms.
to determine whether a small aneurysm rupture is high risk is key to preventing fatal and disabling intracranial bleeding.
, UIAs and isovascular disease (ICVD) are detected with high-resolution MRIs more frequently.
aspirin is a standard secondary preventive drug for ICVD patients.
researchers have not yet clearly determined whether aspirin is safe for patients with ICVD.
aspirin in the short term (3 months) increases the risk of rupture of the aneurysm.
, however, has recently been described as a potential treatment because it prevents aneurysm rupture by exerting anti-inflammatory effects on the walls of aneurysms.
-Cong Weng of Tiantan Hospital in Beijing, China, and others conducted a multi-center prospective cohort study to test aspirin's safety assumptions for patients with unbroigned intracranial aneurysms.
their research team, 1,866 isohemia cerebrovascular disease (ICVD) patients were included in four hospitals from January 2016 to August 2019, all with lesions with a diameter of less than 7mm.
, they record baseline and follow-up patient information, including aspirin use.
main endpoint is an aneurysm rupture.
the main results of the study: 643 patients (37.2%) received aspirin continuously after 4411.4 years (person-years).
all patients, 12 (0.7%) had ruptures.
of vascular rupture (IRR) was 0.27 (95% CI 0.15 s0.48)/100 person years.
IRRs for non-aspirin groups and aspirin groups are 0.39 (95% CI 0.21-0.72) and 0.06 (95% CI 0.010-0.45) /100 years, respectively.
in a multivariable analysis, uncontrolled hypertension and 5-7mm UIS were associated with a high incidence of aneurysm rupture, while the use of aspirin was associated with a low incidence of aneurysm rupture.
high-risk groups (UIAs 5-7mm, accompanied by uncontrollable hypertension) IRRs were higher than in other groups.
of the study is to find that aspirin is a safe treatment for patients with both small UIAs and ICVD.
who do not take aspirin in high-risk groups need to be monitored more closely.
<!--5f39ae17-8c62-4a45-bc43-b32064c9388a: W3siYmxvY2tJZCI6Ijk2OTYtMTYwOTM0NDUxNTE1NCIsImJsb2NrVHlwZSI6InBhcmFncmFwaCIsInN0eWxlcyI6eyJhbGlnbiI6ImxlZnQiLCJpbmRlbnQiOjAsInRleHQtaW5kZW50IjowLCJsaW5lLWhlaWdodCI6MS43NSwiYmFjay1jb2xvciI6IiIsInBhZGRpbmciOiIifSwidHlwZSI6InBhcmFncmFwaCIsInJpY2hUZXh0Ijp7ImRhdGEiOlt7ImNoYXIiOiLpooUifSx7ImNoYXIiOiLlhoUifSx7ImNoYXIiOiLmnKoifSx7ImNoYXIiOiLnoLQifSx7ImNoYXIiOiLoo4IifSx7ImNoYXIiOiLlsI8ifSx7ImNoYXIiOiLliqgifSx7ImNoYXIiOiLoh IkifSx7ImNoYXIiOiLnmKQifSx7ImNoYXIiOiLvvIgifSx7ImNoYXIiOiJzIn0seyJjaGFyIjoibSJ9LHsiY2hhciI6ImEifSx7ImNoYXIiOiJsIn0seyJjaGFyIjoibCJ9LHsiY2hhciI6IiAifSx7ImNoYXIiOiJ1In0seyJjaGFyIjoibiJ9LHsiY2hhciI6InIifSx7ImNoYXIiOiJ1In0seyJjaGFyIjoicCJ9LHsiY2hhciI6InQifSx7ImNoYXIiOiJ1In0seyJjaGFyIjoiciJ9LHsiY2hhciI6ImUifSx7ImNoYXIiOiJkIn0seyJjaGFyIjoiICJ9LHsiY2hhciI6ImkifSx7ImNoYXIiOiJuIn0seyJjaGFyIjoidCJ9LHsiY2hhciI6InIifSx7ImNoYX IiOiJhIn0seyJjaGFyIjoiYyJ9LHsiY2hhciI6InIifSx7ImNoYXIiOiJhIn0seyJjaGFyIjoibiJ9LHsiY2hhciI6ImkifSx7ImNoYXIiOiJhIn0seyJjaGFyIjoibCJ9LHsiY2hhciI6IiAifSx7ImNoYXIiOiJhIn0seyJjaGFyIjoibiJ9LHsiY2hhciI6ImUifSx7ImNoYXIiOiJ1In0seyJjaGFyIjoiciJ9LHsiY2hhciI6InkifSx7ImNoYXIiOiJzIn0seyJjaGFyIjoibSJ9LHsiY2hhciI6InMifSx7ImNoYXIiOiIsIn0seyJjaGFyIjoiICJ9LHsiY2hhciI6IlUifSx7ImNoYXIiOiJJIn0seyJjaGFyIjoiQSJ9LHsiY2hhciI6InMifSx7ImNoYXI iOiLvvIkifSx7ImNoYXIiOiLnmoQifSx7ImNoYXIiOiLmsrsifSx7ImNoYXIiOiLnlpcifSx7ImNoYXIiOiLkuIAifSx7ImNoYXIiOiLnm7QifSx7ImNoYXIiOiLmmK8ifSx7ImNoYXIiOiLnpZ4ifSx7ImNoYXIiOiLnu48ifSx7ImNoYXIiOiLlpJYifSx7ImNoYXIiOiLnp5EifSx7ImNoYXIiOiLpooYifSx7ImNoYXIiOiLln58ifSx7ImNoYXIiOiLpoocifSx7ImNoYXIiOiLlhbcifSx7ImNoYXIiOiLkuokifSx7ImNoYXIiOiLorq4ifSx7ImNoYXIiOiLnmoQifSx7ImNoYXIiOiLor50ifSx7ImNoYXIiOiLpopgifSx7ImNoYXIiOiLjgIIifSx7ImNo YXIiOiLmoIcifSx7ImNoYXIiOiLlh4YifSx7ImNoYXIiOiLnmoQifSx7ImNoYXIiOiLmsrsifSx7ImNoYXIiOiLnlpcifSx7ImNoYXIiOiLmmK8ifSx7ImNoYXIiOiLop4IifSx7ImNoYXIiOiLlr58ifSx7ImNoYXIiOiLov5kifSx7ImNoYXIiOiLkupsifSx7ImNoYXIiOiLnl4UifSx7ImNoYXIiOiLlj5gifSx7ImNoYXIiOiLjgIIifSx7ImNoYXIiOiLlsI8ifSx7ImNoYXIiOiLkuo4ifSx7ImNoYXIiOiI3In0seyJjaGFyIjoibSJ9LHsiY2hhciI6Im0ifSx7ImNoYXIiOiIgIn0seyJjaGFyIjoi55qEIn0seyJjaGFyIjoi5YqoIn0seyJjaGFyIjoi6 ISJIn0seyJjaGFyIjoi55ikIn0seyJjaGFyIjoi5Y2gIn0seyJjaGFyIjoi56C0In0seyJjaGFyIjoi6KOCIn0seyJjaGFyIjoi5YqoIn0seyJjaGFyIjoi6ISJIn0seyJjaGFyIjoi55ikIn0seyJjaGFyIjoi55qEIn0seyJjaGFyIjoiNiJ9LHsiY2hhciI6IjkifSx7ImNoYXIiOiIuIn0seyJjaGFyIjoiNiJ9LHsiY2hhciI6IiUifSx7ImNoYXIiOiIgIn0seyJjaGFyIjoi44O8In0seyJjaGFyIjoiNyJ9LHsiY2hhciI6IjEifSx7ImNoYXIiOiIuIn0seyJjaGFyIjoiOCJ9LHsiY2hhciI6IiUifSx7ImNoYXIiOiIgIn0seyJjaGFyIjoi44CCIn0sey JjaGFyIjoi56GuIn0seyJjaGFyIjoi5a6aIn0seyJjaGFyIjoi5bCPIn0seyJjaGFyIjoi5YqoIn0seyJjaGFyIjoi6ISJIn0seyJjaGFyIjoi55ikIn0seyJjaGFyIjoi56C0In0seyJjaGFyIjoi6KOCIn0seyJjaGFyIjoi55qEIn0seyJjaGFyIjoi5pivIn0seyJjaGFyIjoi5ZCmIn0seyJjaGFyIjoi5Li6In0seyJjaGFyIjoi6auYIn0seyJjaGFyIjoi6aOOIn0seyJjaGFyIjoi6ZmpIn0seyJjaGFyIjoi5pivIn0seyJjaGFyIjoi6ZiyIn0seyJjaGFyIjoi5q2iIn0seyJjaGFyIjoi6Ie0In0seyJjaGFyIjoi5ZG9In0seyJjaGFyIjoi5ZKMIn0 seyJjaGFyIjoi6Ie0In0seyJjaGFyIjoi5q6LIn0seyJjaGFyIjoi5oCnIn0seyJjaGFyIjoi6aKFIn0seyJjaGFyIjoi5YaFIn0seyJjaGFyIjoi5Ye6In0seyJjaGFyIjoi6KGAIn0seyJjaGFyIjoi55qEIn0seyJjaGFyIjoi5YWzIn0seyJjaGFyIjoi6ZSuIn0seyJjaGFyIjoi44CCIn0seyJjaGFyIjoi55uuIn0seyJjaGFyIjoi5YmNIn0seyJjaGFyIjoi77yMIn0seyJjaGFyIjoi55SoIn0seyJjaGFyIjoi6auYIn0seyJjaGFyIjoi5YiGIn0seyJjaGFyIjoi6L6oIn0seyJjaGFyIjoi546HIn0seyJjaGFyIjoiICJ9LHsiY2hhciI6Ik0ifSx7 ImNoYXIiOiJSIn0seyJjaGFyIjoiSSJ9LHsiY2hhciI6IuWQjCJ9LHsiY2hhciI6IuaXtiJ9LHsiY2hhciI6IuajgCJ9LHsiY2hhciI6Iua1iyJ9LHsiY2hhciI6IiAifSx7ImNoYXIiOiJVIn0seyJjaGFyIjoiSSJ9LHsiY2hhciI6IkEifSx7ImNoYXIiOiJzIn0seyJjaGFyIjoiICJ9LHsiY2hhciI6IuWSjCJ9LHsiY2hhciI6Iue8uiJ9LHsiY2hhciI6IuihgCJ9LHsiY2hhciI6IuaApyJ9LHsiY2hhciI6IuiEkSJ9LHsiY2hhciI6IuihgCJ9LHsiY2hhciI6IueuoSJ9LHsiY2hhciI6IueWviJ9LHsiY2hhciI6IueXhSJ9LHsiY2hhciI6IigifSx7I mNoYXIiOiJJIn0seyJjaGFyIjoiQyJ9LHsiY2hhciI6IlYifSx7ImNoYXIiOiJEIn0seyJjaGFyIjoiKSJ9LHsiY2hhc
